yokogawalogo

Make faster, more confident formulation decisions using real-time aggregation kinetics.

Biopharmaceutical formulation teams are under increasing pressure to make faster stability decisions with less material and limited long-term data.

This on-demand webinar explores how high-throughput aggregation kinetic evaluation enables earlier insight, clearer decision-making, and improved reproducibility across development workflows.

What you will learn:

  • Spot aggregation risk earlier—before long-term stability data is available
  • Make more confident buffer and pH decisions using kinetic evidence
  • Resolve conflicting biophysical readouts with better clarity
  • Reduce variability with automated aggregation rate (AR) evaluation

Speakers

Host
Troy Sullivan
Yokogawa Business Development

Mr. Sullivan is a Business Development Consultant with Yokogawa, supporting the Fluence Analytics portfolio. He focuses on helping biopharmaceutical organizations improve process insight and decision-making through advanced analytics and high-throughput measurement technologies.

Presenter
Thorben Hoeltkemeier, PhD
Novartis

Dr. Thorben Höltkemeier is an Expert in Science and Technology at Novartis, based in Basel, Switzerland, where he works within drug product development and biopharmaceutical research. His work focuses on protein aggregation, formulation stability, and the application of high‑throughput and analytical methods to improve biopharmaceutical development. He has contributed to research advancing particle analysis techniques and aggregation kinetics, supporting more robust and predictive formulation strategies.

Presenter
Cédric Thauvin, PhD
Novartis

Dr. Cédric Thauvin is a scientist at Novartis based in Basel, Switzerland, with a background in pharmaceutical sciences, organic chemistry, and polymer chemistry. His work focuses on drug product development and formulation science, including the design of advanced materials and approaches to improve the stability and performance of biopharmaceuticals. He has contributed to research in nanoparticle-based drug delivery systems and polymer-based formulation strategies.

Watch Now